Any current/future new fundraising through debt or equity?

No specific mention of any new fundraising through debt or equity during the call. Gross debt as of June 30, 2025, stands at Rs. 1,185 crores and net debt at Rs. 967 crores, broadly similar to March levels. Future debt movement is expected to depend on working capital needs and business growth trajectory. Management is cautious and will reassess debt reduction or increases in upcoming quarters based on US market dynamics. No indication of equity fundraising discussed in the call.

Any current/future capex/capital investment/strategic investment?

Most new capacity augmentation projects have been completed. Current CAPEX is primarily directed towards maintenance, replacement, and debottlenecking wherever necessary. There is very little CAPEX planned for major expansion or upgrades at this time. The company guided for a CAPEX of about Rs. 400 crores for the year, which will be capitalized incrementally over the quarters. Depreciation expense increased due to commissioning of a new indoor manufacturing facility for the blended business. Future CAPEX impact on depreciation will be reflected as and when assets are capitalized. No large capi

Future growth expectations in sales/revenue/volumes?

US business expected to grow 10%-15% for the full year, supported by volume gains and product launches (4 launched in Q1, 10-15 planned for rest of the year). Rest of World (RoW) generics saw 21% growth in Q1; expected to grow 10%-15% for the full year. India business aims to return to double-digit growth within months; currently working on improving execution and aligning with market norms. New manufacturing facilities ramp-up and cost optimization initiatives expected to improve operating leverage and margins. API business has been muted but showing potential for recovery after pricing press

Future growth expectations in earnings/operating earnings/profits/EPS?

US business expected to grow 10-15% for the full year FY'26, supported by new product launches and market share gains. Rest of the World (RoW) markets anticipated to grow 10-15% for the full year. EBITDA margins before R&D increased by 23% year-on-year, reflecting revenue growth, better gross margin, and improved utilization. R&D expenses increased as per plan, supporting future product pipeline. Net profit grew 15% year-on-year in Q1 FY'26, with EPS rising from Rs. 6.84 to Rs. 7.85. Maintenance CAPEX primarily, with limited expansion, implying focus on operational efficiency rather

Alembic Pharmaceuticals LtdQ2 FY26Pharmaceuticals & Biotechnology

Alembic Pharmaceuticals Ltd Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹825P/E: 21.6Market Cap: ₹16.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→US business expected to grow 10%-15% for the full year, supported by volume gains and product launches (4 launched in Q1, 10-15 planned for rest of the year).
→Rest of World (RoW) generics saw 21% growth in Q1; expected to grow 10%-15% for the full year.
→India business aims to return to double-digit growth within months; currently working on improving execution and aligning with market norms.
→New manufacturing facilities ramp-up and cost optimization initiatives expected to improve operating leverage and margins.
→API business has been muted but showing potential for recovery after pricing pressures stabilize.
→Overall 10% year-on-year revenue growth achieved in Q1, with broad-based growth despite pricing pressures.

Margin guidance

Category 3

→US business expected to grow 10-15% for the full year FY'26, supported by new product launches and market share gains.
→Rest of the World (RoW) markets anticipated to grow 10-15% for the full year.
→EBITDA margins before R&D increased by 23% year-on-year, reflecting revenue growth, better gross margin, and improved utilization.
→R&D expenses increased as per plan, supporting future product pipeline.
→Net profit grew 15% year-on-year in Q1 FY'26, with EPS rising from Rs. 6.84 to Rs. 7.85.
→Maintenance CAPEX primarily, with limited expansion, implying focus on operational efficiency rather than aggressive capacity buildup.
→Debt levels stable, with careful working capital management; debt trajectory to be reassessed in coming quarters.
→Domestic business aiming to return to strong double-digit growth after current challenges.
→Overall, management projects sustainable growth driven by execution, new launches, and market expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of any new fundraising through debt or equity during the call.
→Gross debt as of June 30, 2025, stands at Rs. 1,185 crores and net debt at Rs. 967 crores, broadly similar to March levels.
→Future debt movement is expected to depend on working capital needs and business growth trajectory.
→Management is cautious and will reassess debt reduction or increases in upcoming quarters based on US market dynamics.
→No indication of equity fundraising discussed in the call.

Order book

The transcript provided from Alembic Pharmaceuticals Limited's Q1 FY'26 Earnings Conference Call does not mention any specifics about the current or expected orderbook or pending orders. Key highlights related to business performance, growth, launches, debt, and CAPEX were discussed, but no direct information about orderbook or pending orders was disclosed. - No explicit data or commentary on current or expected orderbook - No details on pending orders were provided during the call - Focus was more on quarterly financial performance, growth outlook, US launches, India business recovery, tariffs, and CAPEX deployment (mainly maintenance) Please let me know if you'd like insights on any other aspect.

Capex plans

→Most new capacity augmentation projects have been completed.
→Current CAPEX is primarily directed towards maintenance, replacement, and debottlenecking wherever necessary.
→There is very little CAPEX planned for major expansion or upgrades at this time.
→The company guided for a CAPEX of about Rs. 400 crores for the year, which will be capitalized incrementally over the quarters.
→Depreciation expense increased due to commissioning of a new indoor manufacturing facility for the blended business.
→Future CAPEX impact on depreciation will be reflected as and when assets are capitalized.
→No large capital allocation planned for setting up manufacturing in the US due to pricing pressure and uncertain tariff impacts.

How does Alembic Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alembic Pharmaceuticals Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Alembic Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio